63 US companies filed quarterly results with the SEC (8-K Item 2.02). We read 34 and called the likely one-week price move. Calls are graded in the open.
Immunocore reported Q3 net product revenue of $102.2 million, a 10% year-over-year growth, and announced the completion of target enrollment for the Phase 3 TEBE-AM trial, with topline overall survival data expected in Q2 2027. The company also has $901 million in cash, cash equivalents, and marketable securities as of September 30, 2026.
OUR ANALYSIS → VIEW 8-K →Anika Therapeutics reported a 10% year-over-year increase in revenue, driven by 17% growth in the Commercial Channel, and raised the lower end of its full-year 2026 revenue guidance and adjusted EBITDA guidance. The company also secured a new 10-year Hyvisc partnership with enhanced economics and reintroduced its Hyaff non-orthopedic OEM product.
OUR ANALYSIS → VIEW 8-K →AirSculpt Technologies reported a decline in revenue and adjusted EBITDA for the third quarter, and reduced its full-year 2026 guidance, but completed a term loan refinancing extending its debt maturity to 2031. The company's results were below expectations, but it remains confident in its strategy for long-term growth.
OUR ANALYSIS → VIEW 8-K →DraftKings reported a 16% increase in revenue for the third quarter, driven by healthy customer engagement and higher Sportsbook net revenue margin, and introduced fiscal year 2027 revenue guidance of $7.35 billion to $7.75 billion, representing a 17% year-over-year increase at the midpoint.
OUR ANALYSIS → VIEW 8-K →CG Oncology's cash position of $984.5 million is expected to fund operations through 2029, and the company is anticipating key milestones, including PIVOT-006 Phase 3 topline data and BLA completion for BCG-unresponsive NMIBC, but no quantified surprises are disclosed in the filing.
OUR ANALYSIS → VIEW 8-K →Koppers reported a year-over-year decline in net income and adjusted EBITDA, despite a 2.8% increase in net sales, due to higher raw material and logistics costs, which is a negative indicator for the stock. The company's record operating cash flow and free cash flow are positives, but may not be enough to offset the decline in earnings and margins.
OUR ANALYSIS → VIEW 8-K →Protara Therapeutics announced financial results for Q3 2026 and provided a business update, including expected completion of enrollment for the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial and a purchase agreement for TARA-002 manufacturing-related assets, with cash and investments of approximately $143 million as of September 30, 2026
OUR ANALYSIS → VIEW 8-K →E.W. Scripps reported Q3 revenue of $545 million, a 3.6% increase from the prior year, driven by strong political advertising revenue, but core advertising revenue decreased 16% due to displacement from political ads. The company is on track to deliver $125-$150 million of enterprise EBITDA growth by 2028 through cost savings and revenue initiatives.
OUR ANALYSIS → VIEW 8-K →TMCI reported a narrower net loss and improved Adjusted EBITDA, with revenue of $48.3 million in the third quarter, and updated its full-year 2026 revenue guidance to $206-210 million, representing a decline of 3% to 1% compared to full-year 2025. The company also reduced its expected Adjusted EBITDA loss for the full year.
OUR ANALYSIS → VIEW 8-K →Moderna reported a 29% revenue growth in the third quarter and increased its full-year revenue growth outlook to 15%-25%, also improving its GAAP operating expense outlook and ending cash balance expectations, driven by the launch of updated COVID vaccines and expansion of its approved respiratory vaccine portfolio.
OUR ANALYSIS → VIEW 8-K →PSQ Holdings, Inc. reported a 67% increase in third-quarter revenue to $7.3 million and a 66% improvement in GAAP operating loss to $3.3 million, with non-GAAP operating income of $0.3 million, also reaffirming its $32 million full-year revenue outlook
OUR ANALYSIS → VIEW 8-K →Humana Inc. reported third quarter 2026 financial results, with adjusted loss per share of $0.70 and raised full year 2026 adjusted EPS guidance to 'at least $9.50', up from the previous expectation of 'at least $9.00'. The company also reported a favorable insurance segment GAAP benefit ratio and strategic expansion of its CenterWell and Medicaid footprints.
OUR ANALYSIS → VIEW 8-K →NHC reported a 6.6% increase in net operating revenues and a 13.8% increase in adjusted net income for the quarter ended September 30, 2026, driven by recent acquisitions, but GAAP net income decreased due to unrealized losses in marketable equity securities
OUR ANALYSIS → VIEW 8-K →InTest Corp reported record quarterly orders of $49.4 million, a 31% increase year-over-year, and EPS of $0.15, exceeding prior-year period's net loss of $0.08, driven by 34% revenue growth and 47.7% gross margin
OUR ANALYSIS → VIEW 8-K →The filing is for Q1 earnings, which is a routine announcement and typically already priced into the stock, with no quantified surprises mentioned in the provided text.
OUR ANALYSIS → VIEW 8-K →Starwood Property Trust reported a GAAP net loss of $389.7 million and Distributable Earnings of $116.8 million, invested $3.2 billion in the quarter, and repurchased $108 million of common shares, but the results are largely in line with expectations and do not contain significant quantified surprises.
OUR ANALYSIS → VIEW 8-K →Elanco Animal Health reported strong Q3 results with 11% revenue growth, 9% organic constant currency growth, and raised full-year guidance, driven by accelerated price growth and expansion of gross margin, with key products Zenrelia and Credelio Quattro reaching new market share highs.
OUR ANALYSIS → VIEW 8-K →OneMedNet Corp reports preliminary revenue of $1 million for Q3 2026, a 242% increase from Q2 2026, and guides $12-14 million in revenue for Q4 2026, pending customer acceptance of delivered data. This represents a significant increase in revenue and suggests strong growth momentum for the company.
OUR ANALYSIS → VIEW 8-K →Minerva Neurosciences' 8-K filing reports third quarter financial results and business updates, with no quantified surprises, and the company remains on track for topline efficacy data from its Phase 3 trial of roluperidone in 2H 2027
OUR ANALYSIS → VIEW 8-K →United Bancorp, Inc. reported diluted earnings per share of $0.25 and net income of $1,401,000 for the three months ended September 30, 2026, which is a decrease from the previous year due to a one-time event, a charge-off of a commercial credit to a single borrower in the amount of $2,953,000
OUR ANALYSIS → VIEW 8-K →The company reported strong third-quarter results with Net income attributable to PAA of $363 million and Adjusted EBITDA of $711 million, and also announced expansion of the Permian JV gathering system and completion of the acquisition of a Powder River Basin gathering system. However, the junior subordinated notes offering and corresponding redemption of preferred securities may generate distrib
OUR ANALYSIS → VIEW 8-K →The company reported strong third-quarter results with Net income attributable to PAA of $363 million and Adjusted EBITDA attributable to PAA of $711 million, also announcing expansion of the Permian JV gathering system and completion of the acquisition of a Powder River Basin gathering system.
OUR ANALYSIS → VIEW 8-K →Franklin Templeton's preliminary fourth quarter and fiscal year results show significant increases in net income, operating income, and assets under management, driven by strong net inflows and growth in key areas such as alternatives, ETFs, and international business.
OUR ANALYSIS → VIEW 8-K →The company's contracted power capacity doubled to 100 MW and completed Bitdeer installations, but also raised $5 million through a private investment in public equity (PIPE) financing, which may lead to dilution.
OUR ANALYSIS → VIEW 8-K →Tredegar Corporation reported a net loss from continuing operations of $(2.8) million, or $(0.08) per diluted share, for the third quarter of 2026, missing expectations and indicating poor execution amidst broader market pressures. The company's Consolidated EBITDA from ongoing operations also decreased to $4.1 million from $18.1 million in the same quarter last year.
OUR ANALYSIS → VIEW 8-K →The company reported strong third-quarter 2026 financial results, with net income increasing to $52.4 million and EBITDA rising to $120.8 million, driven by solid execution across its terminal network and Wholesale business, which more than offset lower retail fuel volumes due to higher pump prices.
OUR ANALYSIS → VIEW 8-K →The company reported a net sales growth of 3.4% and expanded gross margin by 140 basis points in the third quarter, with international sales growing 18.8% and a new $20 million share repurchase authorization, but also reported a net loss of $4.2 million, or $0.19 per diluted share, which includes a SKU rationalization charge of $3.3 million. The company's adjusted net income was $8.4 million, or $
OUR ANALYSIS → VIEW 8-K →Aligos Therapeutics' Q3 2026 financial results show a net loss of $21.9 million and cash reserves of $31.1 million, expected to fund operations into Q1 2027. The company's pipeline progress, including the Phase 2 B-SUPREME study of pevifoscorvir sodium, is on track but lacks quantified surprises to drive a significant stock move.
OUR ANALYSIS → VIEW 8-K →PPL Corp raises long-term EPS growth outlook to 7% to 9% through at least 2030 and announces a $25 billion capital plan for 2027 to 2030, driving average annual rate base growth of 10% over the period.
OUR ANALYSIS → VIEW 8-K →Sylvamo Corp's 8-K filing reports third quarter earnings and announces a put option agreement to sell its Europe business, which is now reported as discontinued operations, with net sales from continuing operations at $645 million and net income from continuing operations at $85 million
OUR ANALYSIS → VIEW 8-K →Canopy Growth Corp reported a 22% increase in net revenue, driven by a 141% increase in international markets cannabis revenue, and a 30% growth in the Cannabis segment, but gross margin decreased to 29% due to reduced reimbursement rates for medical cannabis.
OUR ANALYSIS → VIEW 8-K →Fluor Corporation reported strong Q3 2026 results with revenue up 10% year over year, EPS of $1.16, and a 21% increase in backlog to $34.3 billion, driven by new awards of $10.9 billion, the highest quarterly total in the company's history.
OUR ANALYSIS → VIEW 8-K →The company has entered into a new financing agreement, which includes a $39 million term loan and a $5 million revolving credit facility, with a maturity date of November 5, 2031, and is secured by substantially all of the company's assets, indicating potential covenant pressure and increased debt burden.
OUR ANALYSIS → VIEW 8-K →The company reported its financial results for the three and nine months ended September 30, 2026, and provided a Quarterly Investor Package, but there are no quantified surprises or significant events that would impact the stock price beyond 1.5% in a week.
OUR ANALYSIS → VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →Filed — our read is on its way.
VIEW 8-K →The material filings, RNS and EU notices in one email every market day, read and scored by AI.
Subscribe free →Nov 5 (348) · Nov 4 (277) · Nov 3 (185) · Nov 2 (126) · Oct 30 (64) · Oct 29 (248) · Oct 28 (199) · Oct 27 (164) · Oct 26 (70) · Oct 23 (37) · Oct 22 (131) · Oct 21 (108) · Oct 20 (68) · Oct 19 (30) · Oct 16 (14) · Oct 15 (37) · Oct 14 (23) · Oct 13 (28) · Oct 9 (8) · Oct 8 (20)